Pythiosis is an emerging infectious disease caused by the microorganism Pythium insidiosum, which has a high mortality and morbidity rate.[1] An epidemiological analysis of 1084 cases of human pythiosis showed that India and Thailand are the main foci of the disease, with sporadic cases occurring in China, America and Europe.[1] A strain of P. insidiosum isolated from a patient in Guangzhou was identified using molecular biology, morphology and biological processes.[1] The modified zoospore induction method achieved 250 times higher efficiency than the traditional method within 24 hours, which can help in rapid and sensitive detection of the pathogen.[1] Drug susceptibility testing demonstrated greater efficacy of antibiotics—doxycycline (MIC 4 μg/ml) and azithromycin (MIC 8 μg/ml)—compared to antifungals (MIC > 128 μg/ml).[1] In experiments on immunocompromised mice, oral monotherapy with azithromycin or doxycycline achieved 80–90% survival, while the control group had only 20% survival.[1] These findings suggest that certain antibiotics could be an effective treatment for pythiosis in humans and animals.